Selection And Use of TNF-Α Inhibitors in The Treatment of Ankylosing Spondylitis
Keywords:
ankylosing spondylitis; tumor necrosis factor-α inhibitors; efficiency; safety.Abstract
A review of recommendations for the use of tumor necrosis factor α (TNF-α) inhibitors in patients with ankylosing spondylitis (AS) is presented. The data on the efficacy of TNF-α in patients with AS are presented. On the basis of international and domestic recommendations, indications for the appointment of this therapy, criteria for assessing its effectiveness and safety are formulated.
References
Nasonov E.L., editor. Rheumatology: Clinical guidelines. 2nd ed. Moscow: GEOTAR-Media; 2010.752 c.
Erdes SH.F. Basic principles of therapy for ankylosing spondylitis (ankylosing spondylitis). Scientific and practical rheumatology. 2013; 51 (6): 686-95.
Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012; 71 Suppl 2: i2-45. doi: 10.1136 / annrheumdis-2011-201036.
Wang D, Ma L, Wu D. Efficacy of etanercept in ankylosing spondylitis hip lesions. Joint Bone Spine. 2011 Oct; 78 (5): 531-2. doi: 10.1016 / j.jbspin. 2011.03.023.
Erdes Sh.F. The use of golimumab for ankylosing spondylitis. Scientific and practical rheumatology. 2012; 50 (Supp. 3): 11-6.
Erdes SH.F. Etanercept in the treatment of ankylosing spondylitis. Scientific and practical rheumatology. 2012; 50 (Supp. 4): 28-34.
Haroon N., Inman R.D., Learch T.J., et al. The Impact of TNF inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2013 Oct; 65 (10): 2645-54. doi: 10.1002 / art.38070.
Van den Bosch F., Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) in spondyloarthropathy:
Caporali R., Pallavicini F.B., Filippini M, et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev. 2009 Jan; 8 (3): 274-80.doi: 10.1016 / j.autrev.2008.11.003. Epub 2008 Nov 17.
Sieper J., Poddubnyy D. New evidence on the management of spondyloarthritis. Nat Rev Rheumatol. 2016 May; 12 (5): 282-95. doi: 10.1038 / nrrheum.2016.42. Epub 2016 Apr 7.
Klotz U., Teml A., Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007; 46 (8): 645-60.
Nam J.L., Ramiro S., Gaujoux-Viala C., et al. Efficacy of biological disease- modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014 Mar; 73 (3): 516-28. doi: 10.1136 / annrheumdis-2013- 204577. Epub 2014 Jan 7.
Maxwell L.J., Zochling J., Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015 Apr 18; (4): CD005468. doi: 10.1002/ 14651858. CD005468.pub2.
Ash Z., Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012 Mar; 71 (3): 319-26. doi: 10.1136 / ard. 2011.150995. Epub 2011 Jul 28.
Pulatova Sh.B., Nabieva D.A. Assessment of the impact of mineral metabolism disorders on the quality of life in patients with ankylosing spondyloarthritis // "Neurology" - 2022. - No. 3 (91). -16-18.
Pulatova Sh.B., Nabieva D.A. Assessment of heart damage in different courses of ankylosing spondyloarthritis / ISSN2181-7812 www.tma-journals.uz 2024, №5. 131-135.
